Chronic Use of

NSAIDs

Original Article Frequency of Peptic Ulcer Disease in Patients with Chronic Use of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)

Shakeel Ahmad¹, Muhammad Naeem², Hamid Ullah³ and Liaqat Ali¹

ABSTRACT

Objective: To ascertain how often individuals on chronic nonsteroidal anti-inflammatory Drugs (NSAIDs) develop peptic ulcer disease.

Study Design: A Cross Sectional Study

Place and Duration of Study: This study was conducted at the Department of Gastroenterology, Qazi Hussain Ahmad Medical Complex Nowshera, from June 2022 to June 2023.

Methods: During the study period all patients with endoscopic findings of peptic ulcer and chronic use of NSAIDs were enrolled for the study. Age, gender, current indications for NSAIDs use, and period of NSAID use were noted. Patients were also assessed for other associated risk factors.

Results: During the study period 184 patients had peptic ulcers on endoscopy. In 15.8% (29/184) of individuals, peptic ulcers was caused by chronic NSAIDs use. Arthritis and malignancy related pain were the most common indications for chronic NSAIDs use and diclofenac was the most commonly used NSAIDs. H. pylori-infection was the most common associated risk factor (48%).

Conclusion: Our study showed the significant association of the chronic NSAIDs use and multiple other risk factors with the peptic ulcer disease. It emphasizes cautious use of NSAIDs in high risk patients, particularly who have multiple other risk factors.

Key Words: Peptic Ulcer Disease, Chronic Use, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)

Citation of article: Ahmad S, Naeem M, Hamid Ullah, Ali L. Frequency of Peptic Ulcer Disease in Patients with Chronic Use of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs). Med Forum 2024;35(1):73-75. doi:10.60110/medforum.350116.

INTRODUCTION

Peptic ulcer is one of the most common diseases of the gastrointestinal tract with estimated lifetime prevalence of approximately 5-10% in the general population.¹ It is defined as a breach in the mucosa of the alimentary tract. It is produced when there is imbalance between the aggressive factors like gastric acid, and proteolytic enzyme and protective factors^{2,3} like mucus and bicarbonate secretion and prostaglandins production, combined with superimposed injury from environmental or immunologic agents.⁴

H. pylori infection, cigarette smoking, alcoholism, psychological stress, ischemia, certain medications like

^{1.} Department of Gastroenterology, DHQ Hospital, Mardan.

^{2.} Department of Gastroenterology, Mardan Medical Complex, Mardan.

^{3.} Department of Gastroenterology, Qazi Hussain Ahmad Medical Complex, Nowshera.

Correspondence: Hamid Ullah, Assistant Professor, Qazi Hussain Ahmad Medical complex, Nowshera. Contact No: 0312 9565134 Email: drhamidullah222@gmail.com

Received:	August, 2023
Accepted:	September, 2023
Printed:	January, 2024

chronic NSAIDS and corticosteroid use, antiplatelet and anticoagulants are the common risk factors for peptic ulcer disease. Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely prescribed and marketed to treat pain and inflammation, and are therefore, the leading cause of non-H—Pylori peptic ulcers.⁵

Chronic use of NSAIDs causes suppression of mucosal prostaglandin (PGE2) and direct irritative topical effect. Prostaglandins stimulate mucus and bicarbonate production, and regulates blood flow to the GI tract.⁶ Its inhibition by NSAIDs leads to loss of alimentary protective factors and in combination with multiple environmental risk factors and H. pylori infection leads to peptic ulcer disease.⁷

Peptic ulcer disease predominantly presents with dyspeptic symptoms like epigastric burning sensation, epigastric pain, pyrosis, nausea, vomiting, bloating and belching.⁸ It may sometimes present with complications like anemia, hematemesis, melena, perforation, gastric or duodenal outlet obstruction or peptic stricture. Malignant formation is rare and related to underlying gastritis.^{9,10}

Since H. pylori infection is decreasing, NSAID-related peptic ulcers are rising because of the injudicious use of the NSAIDs without a prescription^{11,12}. The aim of our study is to find out the frequency of Peptic ulcer disease in our population because of chronic NSAIDs use so

METHODS

This is a cross sectional study conducted in the Gastroenterology department of Qazi Hussain Ahmad Medical Complex, Nowshera from June 2022 to June 2023. All patients with endoscopic findings of peptic ulcer and chronic use of NSAIDs were enrolled for the study. Chronic NSAID use is defined as if these medications are taken more than three times a week for more than three months.

Age, gender, current indications for NSAIDs use, and period of NSAID use were noted. Patients were also assessed for associated risk factors like H. pylori infection, alcoholism, smoking, tobacco chewing etc.

RESULTS

During the study period 184 patients had peptic ulcers on endoscopy. In 15.8% (29/184) of individuals, peptic ulcers was caused by chronic NSAIDs use (figure 1). Arthritis and malignancy related pain were the most common indications for chronic NSAIDs use (table 1). Diclofenac was the most commonly used NSAIDs, linked to peptic ulcer in 41.37% (12/29) of individuals (table 2). Duodenal ulcers outnumbered gastric ulcers, 41.37% (12/29) and 34.48% (10/29) respectively (table 3). H. pylori-infection was also noted in 48% (14/29) of the patients (figure 2). Other peptic ulcer risk factors were noted and also shown in figure 2.




Figure 1: Etiological pattern of PUD

Table	No.	1:	Common	indications	for	chronic
NSAI)s use					


Indications	Percentage (N) of
	Patients
Arthritis	38% (11/29)
Malignancy related pain	31% (9/29)
Chronic body aches	10.3% (3/29)
Chronic Headache	10.3% (3/29)
Others	10.3% (3/29)

Table No. 2: NSAIDs Linked to Peptic Ulcers in the Study

Percentage of
Patients with
Peptic Ulcers
41.37%
(12/29)
20.68% (6/29)
20.68% (6/29)
17.24% (5/29)

Table No	. 3: L	ocation	of Peptic	Ulcers in	Patients
I GOIC I W		ocation	or r cpuic	CICCI 5 III	I automus

Type of Ulcer	Percentage of Patients	
	with Peptic Ulcers	
Duodenal Ulcer	41.37% (12/29)	
Gastric Ulcer	34.48% (10/29)	
Ulcers in both stomach	24.13% (7/29)	
and duodenum		





DISCUSSION

Peptic ulcer disease is a well-known complication of NSAID use. Our study showed comparatively high prevalence (approximately 16%) of peptic ulcer disease in patients with chronic NSAIDs use as compared to other studies which showed the prevalence of $6-11\%^{13,14}$.

In our study diclofenac and naproxen/piroxicam are the most common NSAIDs associated with peptic ulcer, which is similar to findings in other studies¹². However, in our study naproxen/piroxicam was the second most common NSAID used as compared to aspirin as in other studies¹². Diclofenac is the most widely prescribed analgesic in our population because of the easy availability and low cost. This finding emphasizes the need for cautious use of this drug, particularly in patients who already have multiple other risk factors for peptic ulcer disease like having a history of prior peptic ulcer or are receiving concurrent steroid treatment.

In our study like most of the other studies, NSAIDs induced duodenal ulcer outnumbered gastric ulcer. According to our data the correlation between NSAID-

Med. Forum, Vol. 35, No. 1

induced peptic ulcers and H. pylori infection exists in approximately half of the patients with peptic ulcer¹⁵. It emphasizes the importance of H. pylori testing and eradication prior to initiation of NSAIDs use¹⁶.

Finally, the research emphasizes how important it is to take into account various other risk variables like drinking alcohol and smoking when discussing NSAID-related peptic ulcers. In summary, this research offers important new information on the prevalence and risk factors of NSAID-induced peptic ulcer disease in local population. With this knowledge, medical professionals may prescribe NSAIDs more cautiously and create individualized treatment plans for individuals who are susceptible to peptic ulcers because of the associated risk factors¹⁷.

CONCLUSION

Our study showed the significant association of the chronic NSAIDs use particularly diclofenac and aspirin with the peptic ulcer disease. It emphasizes cautious use of NSAIDs in high risk individuals, particularly who have multiple other risk factors like H. pylori infection.

Author's Contribution:

Concept & Design of Study:	Shakeel Ahmad
Drafting:	Muhammad Naeem,
	Hamid Ullah
Data Analysis:	Liaqat Ali
Revisiting Critically:	Shakeel Ahmad,
	Muhammad Naeem
Final Approval of version:	Shakeel Ahmad

Conflict of Interest: The study has no conflict of interest to declare by any author.

Source of Funding: None

Ethical Approval: No.122/BKMC dated 15.06.2022

REFERENCES

- 1. Perez-Aisa MA, Del Pino D, Siles M, Lanas A. Clinical trends in ulcer diagnosis in a population with a high prevalence of Helicobacter pylori infection. Alimentary Pharmacol Therapeutics 2005;21(1):65-72.
- Phillips WJ, Currier BL. Analgesic pharmacology: II. Specific analgesics. J Am Acad Orthop Surg 2004;12(4):221-33.
- 3. Narayanan M, Reddy KM, Marsicano E. Peptic Ulcer Disease and Helicobacter pylori infection. Mo Med 2018;115(3):219-224.
- Lanas Á, Carrera-Lasfuentes P, Arguedas Y, García S, Bujanda L, Calvet X, et al. Risk of upper and lower gastrointestinal bleeding in patients taking nonsteroidal anti-inflammatory, antiinflammatory drugs, antiplatelet agents, or anticoagulants. Clin Gastroenterol Hepatol 2015;13(5):906-12.e2
- 5. Lau JY, Sung JJ, Metz DC, Howden CW. A systematic review of the epidemiology of

complicated peptic ulcer: incidence, recurrence, risk factors, and mortality. Gastroenterol 2008;134(Suppl. 1): A32.

- Ehlin AG, Montgomery SM, Ekbom A, Pounder RE, Wakefield AJ. Prevalence of gastrointestinal diseases in two British national birth cohorts. Gut 2003;52:1117–21.
- Rosenstock S, Jorgensen T, Bonnevie O, Andersen L. Risk factors for peptic ulcer disease: a population-based prospective cohort study comprising 2416 Danish adults. Gut 2003;52: 186–93.
- 8. Konturek SJ, Bielanski W, Plonka M, et al. Helicobacter pylori, nonsteroidal antiinflammatory, anti-inflammatory drugs, and smoking in risk patterns of gastroduodenal ulcers. Scand J Gastroenterol 2003;38: 923–30.
- Lassen A, Hallas J, Schaffalitzky de Muckadell OB. Complicated and uncomplicated peptic ulcers in a Danish county 1993–2002: a population-based cohort study. Am J Gastroenterol 2006;101:945– 53.
- Garcia Rodriguez LA, Hernandez-Diaz S. Risk of uncomplicated peptic ulcer among users of aspirin and nonaspirin nonsteroidal anti-inflammatory drugs. Am J Epidemiol 2004;159:23–31.
- Bartholomeeusen S, Vandenbroucke J, Truyers C, Buntinx F. Time trends in the incidence of peptic ulcers and oesophagitis between 1994 and 2003. Br J Gen Pract 2007;57:497–9.
- 12. Hamid S, Yakoob J, Jafri W, Islam S, Abid S, Islam M. Frequency of NSAID induced peptic ulcer disease. J Pak Med Assoc 2006;56(5):218.
- Liang CM, Yang SC, Wu CK, Li YC, Yeh WS, Tai WC, et al. Risk of Recurrent Peptic Ulcer Disease in Patients Receiving Cumulative Defined Daily Dose of Nonsteroidal Anti-Inflammatory Drugs. J Clin Med 2019;8(10):1722.
- Tang CL, Ye F, Liu W, Pan XL, Qian J, Zhang GX. Eradication of Helicobacter pylori infection reduces the incidence of peptic ulcer disease in patients using nonsteroidal anti-inflammatory drugs: A meta-analysis. Helicobacter 2012;17:286– 296.
- 15. Laine L, Curtis SP, Cryer B, Kaur A, Cannon CP. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) program: a randomized comparison. The Lancet 2007;369(9560):465-73.
- Quan C, Talley NJ. Management of peptic ulcer disease unrelated to Helicobacter pylori or (NSAIDs). The Am J Gastroenterol 2002;97(12): 2950-61.
- 17. Kuna L, Jakab J, Smolic R, Raguz-Lucic N, Vcev A, Smolic M. Peptic ulcer disease: a brief review of conventional therapy and herbal treatment options. J Clin Med 2019;8(2):179.